

*Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2005)**

## **UNAUDITED OPERATING RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2023**

This announcement is made by SSY Group Limited (the “Company”) pursuant to Inside Information Provisions (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”)) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2) of the Listing Rules.

The board of directors (the “Board”) of the Company is pleased to announce the following unaudited operating results of the Company and its subsidiaries (together, the “Group”) for the three months ended 31 March 2023 based on its management accounts which have not been audited or reviewed by the auditor of the Company.

Majority of the Group’s sales are conducted in the PRC and are denominated in Renminbi (“RMB”). RMB depreciated by approximately 7.1% when it was translated into Hong Kong dollars (“HK\$”) for the three months ended 31 March 2023 as compared with that for the same period of 2022. As a result, in terms of HK\$, the unaudited turnover of the Group for the three months ended 31 March 2023 increased only by 0.9% as compared with the same period of 2022 to approximately HK\$1,749 million (same period of 2022: approximately HK\$1,733 million). The unaudited gross profit of the Group for the three months ended 31 March 2023 decreased by 1.1% to approximately HK\$1,008 million (same period of 2022: approximately HK\$1,019 million). The unaudited gross profit margin of the Group for the three months ended 31 March 2023 was approximately 57.6%, representing a drop of 1.2 percentage point as compared with the same period of 2022. For the three months ended 31 March 2023, the Group’s unaudited profit attributable to the shareholders of the Company (the “Shareholders”) increased by 19.8% as compared with the same period of 2022 to approximately HK\$363 million (same period of 2022: approximately HK\$303 million).

For the three months ended 31 March 2023, the abovementioned unaudited turnover of the Group of approximately HK\$1,749 million was comprised of the following:

<b>For the three months ended 31 March 2023</b>	<b>Unaudited turnover (HK\$)</b>	<b>Increase/ (decrease) from same period of 2022</b>	<b>% of unaudited turnover</b>
IV solution products (including subcontracting products)			
Non-PVC soft bag IV solution	581 million	15.2%	33.2%
Upright soft bag IV solution	183 million	3.3%	10.5%
PP plastic bottle IV solution	227 million	12.1%	13.0%
Glass bottle IV solution	61 million	(2.8)%	3.5%
Non-IV solution products			
Ampoule injection	267 million	(16.0)%	15.2%
Bulk pharmaceuticals	221 million	(36.4)%	12.6%
Solid preparations	147 million	106.5%	8.4%
Medical materials	43 million	(9.2)%	2.5%
Other products and services	19 million	553.5%	1.1%

**Shareholders and potential investors should note that all financial information contained in this announcement is unaudited. Accordingly, such information shall in no way be regarded as to provide any indication of the audited financial results of the Group for the three months ended 31 March 2023 or any assurance on such audited financial results. Such information may differ from the information to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of compiling such operating results information.**

**Shareholders and potential investors are advised to exercise caution in dealing in the securities of the Company.**

By order of the Board  
**Chow Hing Yeung**  
*Executive Director and Company Secretary*

Hong Kong, 25 April 2023

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.*